Research programme: lipid kinase inhibitors - Carna Biosciences/Gilead
Latest Information Update: 28 Aug 2025
At a glance
- Originator Carna Biosciences
- Developer Carna Biosciences; Gilead Sciences
- Class Antineoplastics; Immunotherapies; Small molecules
- Mechanism of Action Phosphotransferase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2025 No recent reports of development identified for research development in Cancer in Japan
- 28 Aug 2025 No recent reports of development identified for research development in Cancer in USA
- 07 Aug 2023 Early research is ongoing in USA and Japan (Carna Biosciences pipeline, August 2023)